What are the Fund’s objectives?

The Fund's Aims

• To encourage and sponsor vital epidemiological research into the causes of mesothelioma
• To contribute to clinical trials with novel drug therapies for mesothelioma
• To raise awareness of the disease amongst healthcare professionals and the public at large
• To provide good quality up to date information and advice for mesothelioma sufferers and their carers
• To ensure that the Mesothelioma Charter is delivered

How the Fund helps

1. We are the only independent mesothelioma research registered charity in the UK. This means that we accept donations from those wishing to raise money specifically for research into mesothelioma. Often the family and friends of those who have died of mesothelioma will raise money in their loved one’s name, and say it is a comfort to know that every penny raised will go into helping others with the disease, now and in the future.
2. We provide high quality, easy to understand and up to date information on mesothelioma. This includes information about the disease itself, treatments, clinical trials, novel therapies, where to go for more help, and also details of regional asbestos support groups.
3. We expect and actively encourage the Mesothelioma Charter to be progressed as quickly as possible, and its objectives to be embraced by government and employers without delay.
4. We support patient and carer information days held throughout the UK. These have proved immensely beneficial, providing a unique opportunity for those suffering through mesothelioma to put questions directly to leading professionals. Typical subjects include the latest treatments for mesothelioma, clinical trials and research, obtaining compensation, an overview of benefit entitlements, understanding the symptoms of mesothelioma and the latest campaigning information. Questions and comments from the audience are very welcome.
5. We invite applications for high quality mesothelioma research projects in the UK. All applications are independently reviewed and assessed by a panel of experts in this field.

back to About the fund

Page last updated: 6 November 2008